XIDX
HEAL
Market cap1.21bUSD
Nov 12, Last price
1,415.00IDR
Name
Medikaloka Hermina Tbk PT
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
PT Medikaloka Hermina Tbk, together with its subsidiaries, operates a network of hospitals in Indonesia. The company offers services in the areas of medical acupuncture, pediatrics, surgery, plastic and reconstructive surgery, neurosurgery, emergency medicine, forensic and medicolegal, dentistry, clinical nutrition, integrative medicine, cardiology, obstetrics and gynecology, primary care family medicine, nuclear medicine and molecular theranostics, psychiatry, andrology, dietetics, lactation counseling, and dermatology and venereology. It also provides services in the areas of ophthalmology, clinical microbiology, pediatric neurology, occupational, radiation oncology, orthopedics and traumatology, pulmonology, anatomical pathology, clinical pathology, anesthesiology, internal medicine, psychology, radiology, physical medicine and rehabilitation, neurology, sports medicine specialist, aviation specialist, radiation specialist, otorhinolaryngology, occupational therapy, and urology. In addition, the company offers digital subtraction angiography, gastroenterology, IVF clinic, sleep and snoring clinic, pain clinic, growth and development clinic, stem cell, palliative care, perinatology ward, integrated stroke, and medical tourism services. Further, it is involved in investment, service, trading, management consulting, nurse training, and education services. PT Medikaloka Hermina Tbk was founded in 1985 and is headquartered in Jakarta Timur, Indonesia.
Key people
Husen Sutakaria
Acting President Commissioner · since 2025
Hasmoro
President Director · since 1991
Yulisar Khiat
Vice President Director · since 2024
Binsar Parasian Simorangkir
Vice President Director · since 2024
Tan Gunadi
Director · since 2024
Susi Setiawaty
Director, Company Secretary · since 2024
Gidion Hasan
Commissioner · since 2022
Darwin Noerhadi
Commissioner · since 2017
Meijani Wibowo
Commissioner · since 2022
Heridadi
Independent Commissioner · since 2018
Independent Commissioner · since 2018
Amit Varma
Independent Commissioner · since 2020
Valuation
Title IDR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||